ASCO: Is another pan-tumor drug on the horizon? Johnson & Johnson thinks Balversa could be it

The FDA has only approved a handful of therapies to treat tumors based on a biomarker and regardless of their location. With new clinical data, Johnson & Johnson hopes Balversa could be the next drug up for a pan-tumor nod.